Solirna BioSciences

Work on single-stranded RNAi technology that Genesis had been conducting for its subsidiary Solirna Biosciences has also ceased, although it may restart if an existing investor provides additional financing.

Genesis said it once again needs additional financing to allow its subsidiary to demonstrate in vivo proof of principle for its ssRNAi, a milestone that will trigger additional funding by a key investor.

As reported by RNAi News earlier this month, the long-struggling Genesis recently received a commitment from Japanese biotech firm MediBic Group to invest up to NZ$1 million ($750,000) in the planned subsidiary, Solirna BioSciences.

According to Genesis, the primary investor in the subsidiary is Japan's MediBic Group, which is primarily a pharmacogenomics firm but has made investments in RNAi drug shop Intradigm.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.